What Matters Now
CME
Optimizing Comprehensive Molecular Profiling in Advanced NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Anna-Lena Meinhardt, M.D., Ph.D., National Cancer Institute
92% of Peers Changed Their Practice After this Clinical Scenario
CME
After progression on HER2-directed therapy, clinicians must weigh prompt next-line treatment against further molecular testing, amid toxicity, sequencing uncertainty, and patient priorities.
What Matters Now
CME
Optimizing Comprehensive Molecular Profiling in Advanced NSCLC
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Anna-Lena Meinhardt, M.D., Ph.D., National Cancer Institute
Corresponding Scenario
After Progression on HER2-Targeted Therapy: Choosing What Comes Next
See experiences from 300 peers
After progression on HER2-directed therapy, clinicians must weigh prompt next-line treatment against further molecular testing, amid toxicity, sequencing uncertainty, and patient priorities.
How clinicians responded after this Clinical Scenario
65
%
begin unsure how to apply evidence
92
%
will implement a practice change
